NCT02338999View on ClinicalTrials.gov

Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

June 18, 2015

Primary Completion Date

July 14, 2020

Study Completion Date

July 14, 2020

Conditions
Systemic Lupus Erythematosus
Interventions
RADIATION

PET/CT

The combined PET/CT scans provide images that pinpoint the anatomic location of abnormal metabolic activity within the body.

DRUG

Pioglitazone

Increases insulin sensitivity in muscle and adipose tissue, and inhibits hepatic gluconeogenesis.

DRUG

Placebo

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NIH

NCT02338999 - Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE) | Biotech Hunter | Biotech Hunter